期刊文献+

甲亢患者血浆Fib、APTT和D-D水平检测及意义 被引量:6

Detection of Fib,APTT and D-dimer in patients with hyperthyroidism
原文传递
导出
摘要 目的探讨甲状腺功能亢进(甲亢)患者血凝状态。方法检测41例初诊甲亢患者(甲亢组)血浆纤维蛋白原(Fib)、APTT及D-二聚体(D-D)水平,以甲状腺功能正常体检者作为对照组。结果甲亢组血浆APTT水平显著低于对照组[(23.8±4.5)svs.(34.7±5.6)s],Fib、D-DI水平显著高于对照组[(2.8±0.8)g/Lvs.(2.5±0.5)g/L],[(0.45±0.16)g/Lvs.(0.22±0.13)g/L](P<0.05)。结论甲亢患者处于相对高凝状态,此增加了血栓形成风险。 Objective To investigate the coagulation status of patients with hyperthyroidism.Methods The activated partial thromboplastin time(APTT),fibrinogen(Fib)and D-dimer(D-D)levels were detected in 41 patients with newly diagnosed hyperthyroidism,which were compared to those in the healthy persons with normal thyroid function.Results Plasma APTT in hyperthyroid patients was significantly lower than that in the controls[(23.8±4.5)s vs.(34.7±5.6)s](P0.05).Plasma levels of Fib and D-D in hyperthyroid patients were significantly higher than those in the controls[(2.8±0.8)g/L vs.(2.5±0.5)g/L and(0.45±0.16)g/L vs.(0.22±0.13)g/L](P0.05).Conclusion Patients with hyperthyroidism are in a relatively hypercoagulable state,which increases the risk of thrombosis.
出处 《江苏医药》 CAS CSCD 北大核心 2010年第11期1264-1265,共2页 Jiangsu Medical Journal
关键词 甲状腺功能亢进 活化部分凝血酶时间 纤维蛋白原 D-二聚体 Hyperthyroidism Activated partial thromboplastin time Fibrinogen D-dimer
  • 相关文献

参考文献10

  • 1Folsom AIR, Aleksic N, Park E, et al. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities(ARIC) study[J]. Arte rioscler Thromb Vase Biol, 2001,21 (4) : 611-617.
  • 2Cushman M, Lemaitre RN,Kuller LH, et al. Fibrinolytic acti ration markers predict myocardial infarction in the elderly: the Cardiovascular Health Study[J]. Arterioscler Thromb Vasc Bioh 1999,19(3) : 189-190.
  • 3叶任高.内科学[M].北京:人民卫生出版社,2001.294-307.
  • 4朱妍,张真稳,潘云龙,周玮蔚,程英英,施法兴.2型糖尿病及血管并发症患者血浆D-二聚体变化及临床意义[J].江苏医药,2000,26(3):189-190. 被引量:9
  • 5魏玉香,殷宗健,丛玉隆,张立文.肝硬化患者纤溶活性变化与t-PA、PAⅠ的关系[J].山东医药,2004,44(31):12-13. 被引量:1
  • 6张雅青,李晓东.原发性肾病综合征患者血栓前状态的研究[J].血栓与止血学,2008,14(1):25-26. 被引量:10
  • 7Hofbauer LC, Spitzweg C, Heufelder AE. Graves' disease associated with the primary antiphospholipid syndrome[J]. J Rheumatol, 1996,23(8) : 1435-1437.
  • 8Erem C, Ersoz HO, Karti SS, et al. Blood coagulation and fibrinolysis in patients with hyperthyroidism[J]. J ZEndocrinol Invest, 2002,25 (4) : 345-350.
  • 9Burggraaf J, Lalezari S, Emeis J J, et al. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazot[J]. Thyroid, 2001, 11 (2):153 -160.
  • 10Adam SS, Key NS, Greenberg CS. D-dimer antigen:current concepts and future prospects[J]. Blood,2009,113 (13) : 2878- 2887.

二级参考文献9

  • 1[1]CREW RJ,RADHAKRISHNAN J,APPEL G.Complications of the nephrotic syndrome and their treatment[J].Clin Nephrol,2004,62(4):245-259.
  • 2[2]LOWENSTEIN CJ,MORRELL CN,YAMAKUCHI M.Regulation of Weibel-Palade Body Exocytosis[J].Semin Vasc Med,2005,15(8):302-308.
  • 3[3]SAMAMA MM,HORELLOU MH,ELALAMY I,et al.D-dimer levels,constitutional thrombophilia,and venous thrombosis prediction:clinical aspects and implications[J].Semin Vasc Med,2005,5(4):371-374.
  • 4[4]Verspyck E,Le Cam-Duches V,Borg JY,et a1.Inherited thrombophilia and pregnancy[J].J Gynecol Obstet BiolReprod,2000,29(3):227-229.
  • 5[5]SCHAFER AI.The hypercoagulable states[J].Ann Intern Med,1985,102(6):814-828.
  • 6阮长耿,血栓与止血,1994年,133页
  • 7王新佳,中华神经精神科杂志,1988年,21卷,59页
  • 8Huber K,Kirchheimer JC,Korninger C,et al.Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis.Thromb Res,1991,62(5):491~500.
  • 9Paramo JA,Rocha E.Hemostasis in advanced liver disease.Semin Thromb Hemost,1993,19(3):184~190.

共引文献490

同被引文献71

  • 1周敏(综述),徐酉华(审校),李晓辉(审校).川崎病血液高凝状态的研究进展[J].国际儿科学杂志,2007,34(3):190-192. 被引量:22
  • 2陈灏珠.实用内科学[M]12版.北京:人民卫生出版社,2005.1746-1750.
  • 3Erem C, Ersoz I-IO, Karti SS ,et al. Blood coagulation and fibrinoly- sis in patients with hyperthyroidism[ J]. J Endocrinol Invest,2002, 25(4) :345-350.
  • 4Parker LJ, Lawson DH. Death from thyrotoxicosis [ J ]. Lancet, 1973,2 (7834) :894-895.
  • 5Loeliger EA,van der Esch B ,Mattem MJ ,et al. The biological dis- appearance rate of prothrombin, factor V~, IX and X from plasma in hypothyroidism, hyperthyroidism, and during fever [ J ]. Thromb Diath Haemorrh, 1964,10:267-277.
  • 6Kellet HA, Sawers JA, Boulton FE, et al. Problems of anticoagula- tion with warfarin in hyperthyroidism [ J ]. Q j Med, 1986, 58 (225) :43-51.
  • 7Marongiu F ,Conti M, Mameli G, et al. Fibrinogen and fibrlnolytic activity in hyperthyroidism before and after antithyroid treatment [ J ]. J Endocrinol Invest, 1988,11 ( 10 ) :723-725.
  • 8Marongiu F, Conti M, Murtas ML, et al. Activation of blood coagu- lation and fibrinolysis in Graves' disease [ J ]. Horm Metab Res, 1991,23(12) :609-611.
  • 9Burggraaf J, Lalezari S, Emeis JJ, et al. Endothelial function in pa- tients with hyperthyroidism before and aftert reatment wit proprano- lol and thiamazol[ J]. Thyreid,2001,11 (2) :153-160.
  • 10Adam 55, Key NS, Greenberg GS. D-dimer antigen:current concepts and fut~e prospects [ J ]. Blood,2009,113 ( 13 ) :2878 -2887.

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部